Anjana Sreenivasan, Lekshmipriya KS, Meenu Vijayan, Praveen G Pai
Anjana Sreenivasan1, Lekshmipriya KS2, Meenu Vijayan3, Praveen G Pai4*
1Pharm D, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
2Pharm D, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
3Assistant Professor, Department of Pharmacy Practice, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
4Assistant Professor, Department of Cardiology, Amrita Institute of Medical Sciences, Amrita Vishwa Vidyapeetham, Kochi, 682041, Kerala, India.
Volume - 15,
Issue - 8,
Year - 2022
Atorvastatin is the most widely used statin for the prevention and treatment of cardiovascular disease. It belongs to the class of drugs called HMG-CoA reductase inhibitors. One of the most significant side effects of statins is liver injury. Liver injury as evidenced by elevation in liver enzymes occurs in some patients treated with atorvastatin 10mg to 80mg. Therefore, Liver function tests (LFTs) need to be assessed before initiating atorvastatin therapy and to be repeated thereafter. Here we discuss three cases of liver enzyme elevations within 24hrs of atorvastatin treatment. Liver enzymes were completely returned to baseline after discontinuing the therapy. The risk factors of atorvastatin induced liver injury are increased age, chronic diseases, and coadministration of drugs metabolised by Cytochrome P450 3A (CYP3A) enzyme.
Cite this article:
Anjana Sreenivasan, Lekshmipriya KS, Meenu Vijayan, Praveen G Pai. Atorvastatin induced liver injury: A Case Series. Research Journal of Pharmacy and Technology. 2022; 15(8):3507-0. doi: 10.52711/0974-360X.2022.00588
Anjana Sreenivasan, Lekshmipriya KS, Meenu Vijayan, Praveen G Pai. Atorvastatin induced liver injury: A Case Series. Research Journal of Pharmacy and Technology. 2022; 15(8):3507-0. doi: 10.52711/0974-360X.2022.00588 Available on: https://rjptonline.org/AbstractView.aspx?PID=2022-15-8-30
1. Bhardwaj SS, Chalasani N. Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin Liver Dis. 2007 Aug; 11(3):597-613. doi: 10.1016/j.cld.2007.06.010
2. Saad Antakli, Leon Nejem, Ahmad Kullah. Determination of Pravastatin Sodium by analytical Spectrophotometry. Research J. Pharm. and Tech. 2021; 14(2):741-746. doi: 10.5958/0974-360X.2021.00129.3
3. Dhabale PN, Jadhav V, Raut C. UV-Spectrophotometric Estimation of Atorvastatin Calcium in Tablet Dosage Form. Asian Journal of Research in Chemistry. 2010;3(2):339-41.
4. Ashna A, Jeena S, Vidhya PV, Venkateswaramurthy. N, Sanbathkumar. R. Statins: Pleotropic Effect. Research J. Pharm. And Tech.2016;9(7):977-981. doi:10.5958/0974-360X.2016.00187.6
5. Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012 Feb; 56(2):374- 80. doi: 10.1016/j.jhep.2011.07.023.
6. Vijayakumar M et al. A randomized study of coconut oil versus sunflower oil on cardiovascular risk factors in patients with stable coronary heart disease. Indian Heart Journal. 2016 Jul; 68(4):498-506. doi: 10.1016/j.ihj.2015.10.384
7. Rajesh K, Rajalakshmi R, Vijayaraj S, Sreelakshmi T. Simultaneous estimation of atorvastatin calcium and felodipine by UV-spectrophotometric method in formulation. Asian Journal of Research in Chemistry. 2011 Aug 28;4(8):1202-5
8. Tyseer Shamran Al- Dereswami, Akmam Ali Hbeeb. The side effects of the atorvastatin on liver of hyperlipidemia patients. Research J. Of Pharm and Tech 2019; 12(9):4310-4312. doi:10.5958/1974-360X.2019.00741.8
9. Girish Degavi, Preeti R Bhupali. Knowledge regarding cardiac rehabilitation among staff nurses. Asian J. Nur. Edu. and Research 5(1): Jan.-March 2015; Page 87-93. doi: 10.5958/2349-2996.2015.00019.1
10. Russo MW, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014 Aug; 60(2):679-86. doi: 10.1002/hep.27157
11. Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 Nov; 333(20):1301-7. doi: 10.1056/NEJM199511163332001
12. Liu Y, Cheng Z, Ding L, Fang F, Cheng KA, Fang Q et al. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin. Int J Clin Pharmacol Ther. 2010 Dec; 48(12):798-802. doi: 10.5414/cpp48798
13. Thapar M, et al. Statins and liver injury. Gastroenterology & hepatology. 2013 Sep; 9(9):605
14. Jinan Hussein Murtadha, Iman Hashim, Abdul Razzaq. Study of Liver Function and Lipid Profile Changes in Iraqi Cirrhotic patients. Research J. Pharm. and Tech. 2020; 13(4):1837-1840. doi: 10.5958/0974-360X.2020.00331.5
15. Danan G et al. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993 Nov; 46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6